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Abstract 
Introduction 
From a prospective multi-center multi-country clinical trial, we developed and validated risk 
models to predict prospective all-cause mortality and HF-hospitalizations in patients with heart 
failure (HF). 
Methods 
BIOSTAT-CHF is a research program designed to develop and externally validate risk-models to 
predict all-cause mortality and HF-hospitalizations. The index cohort consisted of 2,516 
patients with HF from 69 centres in 11 European countries. The external validation cohort 
consisted of 1,728 comparable patients from 6 centres in Scotland, UK 
Results 
Patients from the index cohort had a mean age of 69 years, 27% were female, 83% were in 
NYHA class II-III and the mean left ventricular ejection fraction was 31%. The full prediction 
models for mortality, HF-hospitalization and the combined outcome, yielded c-statistic values 
of 0.73, 0.69, and 0.71 respectively. Predictors of mortality and HF-hospitalization were 
remarkably different. The 5 strongest predictors of mortality were a greater age, higher BUN 
and NT-proBNP, lower hemoglobin and failure to prescribe a beta-blocker. The 5 strongest 
predictors of HF-hospitalization were greater age, previous HF-hospitalization, presence of 
edema, lower SBP and lower eGFR. Patients from the validation cohort were 74 years, 34% 
were women, 85% were in NYHA II-III and mean LVEF was 41%; c-statistic values for the full and 
compact model were comparable to the index cohort.  
Conclusion 
A small number of variables, which are usually readily available in the routine clinical setting, 
1  
provide useful prognostic information for patients with heart failure. Predictors of mortality 
were remarkably different from predictors of HF-hospitalization.  
 
BIOSTAT-CHF was funded by a grant from the European Commission (FP7-242209-BIOSTAT-
CHF; EudraCT 2010-020808-29) 
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Introduction 
 
 
Accurately predicting risk of mortality or heart failure hospitalization in patients with heart 
failure (HF) might lead to intensified monitoring and treatment (1–8) and help physicians, 
nurses and patients in making better management decisions (9). Also, selecting high risk 
patients in phase III drug and device trials may enrich clinical event rates and decrease sample 
size. 
 
Many risk prediction models for patients with HF have been published (10). Of 117 models 
included in a recent meta-analysis, only 33% were validated in a separate cohort. Most of these 
models performed only moderately (c-statistic values 0.71, 0.63, and 0.68, for mortality, HF-
hospitalization or their composite respectively) (10–14). Patient-data in these models were 
derived predominantly from randomized controlled intervention trials, which enroll highly 
selected and motivated patients who volunteer for research, or from administrative data-sets, 
such as medical insurance claims, that often have diagnostic inaccuracies and fail to record key 
clinical data such as the blood pressure or a measure of renal function.  
 
BIOSTAT-CHF is a large European project, which was specifically designed to develop and 
validate risk prediction models in patients with HF (15). In the present report we provide the 
principal findings of this study.
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Methods 
The Transparent Reporting of a multivariable prediction model for Individual Prognosis Or 
Diagnosis (TRIPOD) recommendation was used as a guideline in developing and validating our 
prediction models (16). 
 
Patient index and validation cohort 
Our models were developed using data from the BIOSTAT-CHF cohort (15). In short, BIOSTAT-
CHF enrolled an index cohort of 2,516 patients from 69 hospital centers in 11 European 
countries predominantly during 2010-2014 and a comparable validation cohort of 1,738 
patients from 6 centers in Scotland, UK enrolled predominantly during years 2010-2014. 
Patients were enrolled as in-patients or from outpatient clinics. The median follow-up in 
each cohort was 21 months with an interquartile range of 15 and 27 months respectively. 
Patients from the index cohort were aged >18 years with symptoms of new-onset or 
worsening HF, confirmed either by a left ventricular ejection fraction (LVEF) of ≤40% or 
B-type Natriuretic Peptide (BNP) and/or (N-terminal pro) B-type natriuretic peptide (NT-
proBNP) plasma levels >400 pg/ml or >2,000pg/ml, respectively, treated with either oral or 
intravenous furosemide ≥40 mg/day or equivalent at the time of inclusion. BIOSTAT-CHF was 
also designed to establish the effects of and response to initiation and up-titration of and 
response to guideline directed medical therapy. Therefore, in order to be considered for 
enrollment in either cohort, patients had either not to be treated with an ACE-inhibitor/ARB 
and/or beta-blocker or had to be treated with ≤50% of target doses of these therapies at the 
time of inclusion and with an anticipated initiation or up-titration of such therapy by the 
treating physician. 
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Patients from the validation cohort were aged >18 years with a HF diagnosis based on 
echocardiographic evidence of left ventricular dysfunction or a previous documented 
admission with HF treated with furosemide ≥20 mg/day or equivalent. 
During follow-up, patients underwent a second visit at 9 months after inclusion. Every 6 
months, patients were contacted  usually by telephone, to collect information on medication 
and clinical events. 
 
 
Outcomes and predictor variables 
Primary outcomes were time to all-cause mortality, first HF-hospitalization and the composite 
outcome of all-cause mortality and HF-hospitalization. 
 
Using a Cox proportional hazards model, we evaluated the  predictive value of 42 demographic, 
clinical and biochemical variables that were measured at inclusion. These variables were 
selected, since previous studies identified those factors to be associated  with mortality and 
hospitalization. An overview of the predictor variables and summary statistics are available in 
supplemental table (S1). 
 
Non-linearity of the log-hazard for variables with quantitative values were evaluated using 
restricted cubic splines (17). For the non-linear variables transformations to linearity were 
applied (e.g. log-transformation or square root) and re-tested using cubic splines. The 
proportional hazards assumption of the Cox model was assessed using Schoenfeld residuals 
and the Therneau and Grambsch non-proportionality test (18). 
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Missing predictor values were imputed using multi-chain Monte Carlo methods with Gibbs 
sampling. We used the R-package ‘mice’ (19). We imputed missing data five times, performed 
the analysis over all five imputations and averaged results using Rubin’s rules (19). 
 
Model Development 
We conducted stepwise backward regressions on the predictor variables by Akaike information 
criterion (AIC) in 1000 bootstrap samples for each imputation set (20). We chose variables for 
our full model when predictor variables were selected in more than 40% of all 5×1000 
bootstrap samples. In addition, to make our models more applicable in medical practice, we 
developed a reduced compact model with a maximum of five predictor variables in the 
mortality and HF-hospitalization models and ten in the composite model. We used variables 
selected in the compact model to develop a simplified risk score, using a decision tree 
algorithm (21), and calculated survival probabilities using Cox regression for all three 
outcomes. 
 
Model Validation 
We first validated our models internally correcting the raw c-statistic (22) for optimism by 1000 
bootstrap sampling in the five imputation sets. We used the procedure suggested by Musoro et 
al (23). Second, we validated our models externally in the validation cohort data. For all 
patients in this cohort we calculated the risk score using the Cox-regression weights estimated 
from the index cohort and subsequently calculated the c-statistic for the validation cohort. We 
then compared the distribution of prediction scores in the index cohort with the distribution of 
those from the validation cohort. We also applied two prediction models (the Seattle Heart 
Failure Model (SHFM) (24) and the MAGGIC (25) mortality scores) to the BIOSTAT-CHF cohort 
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and compared c-statistic values to our developed models. Additionally, we compared c-statistic 
values in our models for patients with either HFrEF or HFpEF in the index and validation 
cohorts. 
 
 
 
Results 
 
 
Patients in the index cohort (n=2516) had a mean (±SD) age of 69 (±12) years, 27% were 
female, 83% were in NYHA II-III with a mean (±SD) LVEF of 31 (±11)%, and 162 (7%) had a 
LVEF>45%. Further details were previously published, and baseline characteristics of both 
cohorts are described in supplementary table 1 (15). Most patients were enrolled during an 
admission for worsening heart failure (55%). During a median follow-up of 21 [15-27] months, 
657 (26%) patients died, 613 (24%) were hospitalized at least once for worsening HF and 1,019 
(41%) had a first event of either death or HF-hospitalization. Patients in the validation cohort 
(n=1738) had a mean (±SD) age of 74 (±11) years, 34% were female. 85% were in NYHA II-III 
with a mean (±SD) LVEF of 41(±13)%, and 529 (34%) had a LVEF>45% (15). Most patients in this 
cohort were enrolled as out-patients (46%). During a median follow-up of 21 [11-32] months, 
589 (34%) patients died and 610 (35%) were hospitalized for worsening of HF, and 894 (51%) 
had a first event of either death or HF-hospitalization. 
 
Model Development index cohort 
Full models 
The proportional hazards assumption for the linear effect of the variables on mortality-, HF-
hospitalization--risk and the risk of the composite outcome was applicable to all variables. The 
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final full models included those variables that appeared in >40% of the bootstrap analyses 
(supplementary figure S1), which for mortality consisted of 16 variables (Table 1) and yielded 
a raw c-statistic of 0.73 (0.73 after correction for optimism). The relation of each variable with 
the outcome variables are presented in supplementary table S2. The final full model to predict 
HF-hospitalization incorporated 10 variables, which achieved a raw c-statistic of 0.69 (0.68 
after correction for optimism). The final full model to predict the composite outcome 
consisted of 15 variables, which had a raw c-statistic of 0.71 (0.70 corrected for optimism). 
 
Compact models 
The final compact mortality model included 5 variables that appeared in more than 70% of the 
bootstrap analyses. Greater age, higher blood urea nitrogen (BUN) and NT-proBNP, lower 
hemoglobin and failure to prescribe a beta-blocker predicted a higher mortality with a raw c-
statistic of 0.69 (0.69 after correction for optimism). The final compact model to predict HF-
hospitalization included 5 variables that appeared in more than 60% of the bootstrap analyses. 
Greater age, HF-hospitalization in year prior to inclusion, presence of edema, lower systolic 
blood pressure (SBP) and lower estimated glomerular filtration rate (eGFR) predicted an 
increased risk of HF hospitalization with a raw c-statistic of 0.67, and 0.66 after correcting for 
optimism. The final compact model to predict the combined endpoint included 9 variables that 
appeared in more than 70% of the bootstrap analyses. Greater age, HF-hospitalization in the 
year prior to inclusion, presence of edema, higher NT-proBNP, lower SBP, hemoglobin, HDL-
cholesterol, and serum sodium concentration and failure to prescribe a beta-blocker predicted 
the composite outcome with a raw and optimism corrected c-statistic value of 0.69. 
 
Point score model 
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For the risk score we used the variables from the compact model. The decision tree algorithm 
selected the following cut-off points for optimal classification: NT-proBNP >4000 pg/ml, BUN 
>11 mmol/l, HDL <1.05 mmol/l, age >70 years, sodium <140 mmol/l, hemoglobin (HB) <12 
g/dL, eGFR (CKD-EPI formula) <40 ml/min and SBP <140 bpm.  
A score for each patient was subsequently calculated by adding one point for each ‘adversely’ 
affected variable, resulting in a score range of 0-5, 0-5, 0-9 for mortality, hospitalization, and 
the combined endpoint respectively. Kaplan Meier survival curves for each score were then 
calculated (figure 1). The risk scores can be calculated using the online calculator which can be 
found at: http://www.biostat-chf.eu 
 
In the validation cohort, the c-statistic for the full models were 0.73, 0.64, and 0.68 for 
mortality, HF-hospitalization and their composite, respectively and 0.72, 0.61, and 0.67 for the 
compact models. The two-year event rates for risk scores were almost uniformly higher in the 
validation cohort (figure 1). Calibration plots are presented in supplementary figures S2 and S3. 
Applying the SHFM and MAGGIC mortality scores to our cohort achieved a similar c-statistic 
(0.68) to the BIOSTAT compact model. 
 
Difference between HFrEF and HFpEF 
In the index cohort, for mortality, HF-hospitalization, and their composite, the final full models 
yielded c-statistics of 0.73, 0.69, and 0.71 for HFrEF and 0.65, 0.61 and 0.62 for HFpEF and for 
the compact models 0.69, 0.67, and 0.70 for HFrEF and 0.64, 0.62 and 0.61 for HFpEF. These 
differences between HFrEF and HFpEF patients in the index cohort were not present in the 
validation cohort, as presented in table 4. The final full mortality, HF-hospitalization, and their 
composite models yielded c-statistic values 0f 0.74, 0.63, and 0.68 for HFrEF and 0.72, 0.64 and 
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0.69 for HFpEF and for the compact models 0.72, 0.62, and 0.67 for HFrEF and 0.71, 0.61 and 
0.67 for HFpEF.  
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Discussion 
 
This analysis demonstrates that a small number of readily available clinical variables predict 
outcome consistently and with reasonable accuracy in two patient populations with 
symptomatic HF. Predictors of mortality were remarkably different from predictors of HF-
hospitalization.  
 
We recently published a meta-analysis on all available risk-prediction models in patients with 
HF (10). In 117 models, 249 different variables were used. The mean c-statistic across all 
models was 0.71, 0.63 and 0.68 for predicting mortality, HF-hospitalization, or their composite, 
respectively. The BIOSTAT-CHF prediction model for mortality therefore performed slightly 
better than average. This is remarkable, since BIOSTAT-CHF included much broader and more 
heterogeneous populations, closer to routine clinical practice, than the populations providing 
the data for most other HF risk prediction models (10–12). 
We provided outcomes of both a full models that included variables that appeared in more 
than 60% of the bootstrap analyses and compact models that included variables that 
appeared in more than 70% of the bootstrap analyses. The advantage for the full model 
are a better predictive value. Given the high number of events, the number of variables 
that are used in the full model was statistically allowed. The advantage of the full model is 
that it does justice to the complexity of the large number of factors that determine 
prognosis of patients. The advantage of the compact model is that it is easier to use, but its 
limitations should be taken into account.  
We also compared our risk scores to two other more complex models based mainly on clinical 
trial populations; the Seattle Heart Failure Model (SHFM) (24) and the MAGGIC (25) which 
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reported c-statistics of 0.72 and 0.74 respectively for predicting mortality (24,26). C-statistic 
values of the SHFM and MAGGIC mortality scores to our cohort achieved a similar c-statistic 
(0.68) to the BIOSTAT compact model. This supports the hypothesis that our patient population 
is more heterogeneous, making it more difficult to achieve accurate predictions. 
 
The majority of currently existing prognostic models in patients with heart failure are based on 
data from randomized controlled trials or extracted from administrative data-sets, such as 
medical insurance claims. Patients selected for clinical trials are generally a highly selected 
group of volunteers that have few serious co-morbidities and a high disease burden. 
Administrative datasets often do not include the detailed medical data needed to develop 
accurate prediction models. BIOSTAT-CHF included a broad cohort of patients in Europe, with a 
very limited number of in- and exclusion criteria. And therefore more accurately reflects 
patients with HF in daily clinical practice.  
 
Similar to many other risk prediction models, we found that the accuracy to predict mortality 
was moderate, but the model was less accurate at predicting HF-hospitalization. This might be 
because worsening evidence of HF is not the sole or even dominant factor precipitating 
hospitalization. Co-morbidity, frailty, community heart failure services, ability to manage life-
style and medications, social support networks and cultural factors poorly related to disease 
severity may all be important determinants of hospitalization (27). Accordingly, no relation has 
been found between early readmissions and mortality after a first hospitalization (28–31) 
 
The variables that were included in the  mortality models were  different from those of the HF-
hospitalization . The only variable included in all compact models was age. The majority of our 
 12 
predictors of HF-hospitalization have been described in other models as well. In particular, a 
previous HF-hospitalization identifies patients at greater risk of (re)hospitalization; it was 
associated with a more than doubled risk of repeat HF-hospitalization (32). This variable 
therefore might identify an especially vulnerable patient-group in which fluid balance is easily 
disrupted, hence causing signs and symptoms of congestion warranting admission and 
intravenous diuretic treatment. The finding that edema is also a marker of increased 
hospitalization risk but not of mortality supports this notion and suggests that the underlying 
pathology might differ significantly (33).  
 
In our mortality model, BUN was an independent predictor, while eGFR was a predictor of re-
hospitalizations. BUN is one of the strongest predictors of adverse outcome in HF, and the 
information captured by this marker is often thought to encompass more than renal function 
alone (34,35). However, eGFR and BUN are strongly correlated and this in part explains the 
absence of BUN in the hospitalization model and the absence of eGFR in the mortality model. 
 
Interestingly, serum sodium and HDL are only included in the compact models for the 
combined endpoint. The inclusion of HDL in these models was not expected beforehand, yet in 
one report on a small population of patients with advanced HF, HDL was the strongest 
predictor of an adverse outcome (36). Traditionally, HDL has been associated with the risk of 
atherosclerosis, however recent evidence showed that the HDL proteome also plays an 
important role in inflammation (37). Hyponatremia is a well-recognized predictor of poor 
outcome in both acute and chronic HF and it is therefore not surprising that low serum sodium 
is associated with an increased risk of the combined endpoint (38,39). The use of a beta-
blocker at baseline was associated with a lower risk of mortality and the combined endpoint. 
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The inclusion of beta-blocker use in our model might be confounded by disease severity 
influencing tolerability of beta-blockers creating a potential selection bias. In addition, 
suboptimal medical treatment was an inclusion criterion for our study. However, it may also 
confirm the importance of the use of beta-blockers in HF and its effect on improved outcome. 
Further analyses of the BIOSTAT-CHF study will attempt to determine the determinants and 
clinical outcome related to inadequate up-titration of ACE-inhibitors and/or beta-blockers.  
 
 
Limitations and Strengths 
The BIOSTAT-CHF cohort is a European multi-national prospective cohort. Healthcare systems 
and patient treatment between the different European countries vary greatly. This might 
influence management, outcome and prediction, although all investigators were encouraged to 
follow the recommendations of the ESC HF Guidelines (2). However, because of the multi-
national character of this cohort, the results will be highly generalizable. Our validation cohort 
consisted only of patients from Scotland. This cohort might not resemble the heterogeneity of 
the European patient population. However, this cohort was a completely independent 
validation cohort with no ties to the index cohort. Both cohorts selected patients who were 
sub- optimally treated with ACE-inhibitors/ARBs and/or beta-blockers, which might further 
limit the generalizability of the results.  
Events were not adjudicated by an adjudication committee, but by the treating physicians. 
However, a systematic meta-analysis failed to detect any effect of event adjudication on study 
conclusions of cardiovascular outcome trials and the numbers of events included in the final 
analyses were minimally changed (40). 
With regards to the hospitalization endpoint, competing risks need to be taken into account 
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(i.e. if a patient died, he/she cannot be hospitalized anymore).  Both in the index and validation 
cohorts, BIOSTAT-CHF included patients with HFrEF and HFpEF. This can be regarded as both a 
strength and a limitation. The HFpEF patients in the index cohort were limited to those patients 
with NT-proBNP levels >2000 pg/mL, thereby increasing the reliability of the diagnosis but 
reducing its prevalence and excluding milder cases. There were small differences in c-statistic 
values between HFrEF and HFpEF in the index cohort, but in the validation cohort, the 
prediction model performed similarly in patients with either HFpEF or HFrEF. However, given 
the low number of HFpEF patients in the index cohorts, these data should be carefully 
interpreted. Finally, the large majority of patients (99%) was Caucasian which limits the 
generalizability of the models. 
 
Conclusion 
We developed and validated models for predicting mortality, HF-hospitalization and the 
combined outcome of mortality and HF-hospitalization. Variables that were included in the  
mortality models were remarkably different from those in the  HF-hospitalization models. In 
addition, we presented a simplified risk score for use in clinical practice. In comparison with 
well-known existing prediction scores, our developed models performed better in this patient 
population. 
 
 
BIOSTAT-CHF was funded by a grant from the European Commission (FP7-242209-BIOSTAT-
CHF; EudraCT 2010-020808-29). NJS holds a Chair funded by the British Heart Foundation and is 
an NIHR Senior Investigator.  
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Table 1: Results of the Cox Proportional Hazards analysis for the full models predicting 
mortality, HF-hospitalization and the combined endpoint. 
 
Mortality  HF-Hospitalization                 Combined endpoint 
  HR 95% CI p HR 95% CI P HR 95% CI p 
Age (years) 1.03 (1.02-1.04) <0.0001 1.01 (1.00-1.02) 0.0005 1.02 (1.01-1.03) <0.0001 
Ischemic etiology 1.36 (1.16-1.61) 0.0002 
  
  
   
Heart failure 
hospitalization in last 
year  
  
  1.68 (1.43-1.98) <0.0001 1.46 (1.28-1.67) <0.0001 
Smoking 
  
  
  
  
   
          No 
  
  
  
  
 
- - 
          Past 
  
  
  
  1.12 (0.97-1.28) 0.1267 
          Current 
  
  
  
  1.42 (1.15-1.75) 0.0012 
DM 
  
  1.32 (1.12-1.57) 0.0009 
   
COPD 1.28 (1.07-1.54) 0.0084 
  
  1.17 (1.01-1.37) 0.0374 
NYHA class 
  
  
  
  
   
          NYHA class I 
  
  
  
  
 
- - 
          NYHA class II 
  
  
  
  1.17 (0.66-2.08) 0.5822 
          NYHA class III 
  
  
  
  1.46 (0.83-2.57) 0.1813 
          NYHA class IV 
  
  
  
  1.42 (0.79-2.56) 0.2441 
Peripheral edema 1.32 (1.11-1.58) 0.0021 1.28 (1.07-1.53) 0.0052 1.25 (1.08-1.44) 0.002 
Elevated Jugular venous 
pressure   
  
  
  
   
          No 
 
- - 
 
- - 
 
- - 
          Yes 1.25 (1.00-1.55) 0.0482 1.34 (1.10-1.62) 0.0029 1.22 (1.05-1.42) 0.0084 
Uncertain 1.14 (0.80-1.62) 0.4498 1.31 (0.89-1.93) 0.1725 1.16 (0.83-1.63) 0.3984 
DBP (mmHg) 0.99 (0.98-1.00) 0.0037 
  
  
   
SBP (mmHg) 1.00 (0.99-1.01) 0.2962 0.99 (0.99-0.99) <0.0001 0.99 (0.99-0.99) 0.0003 
eGFR (CKD-EPI 
formula)(ml/min)   
  0.99 (0.99-0.99) <0.0001 0.99 (0.99-0.99) 0.0064 
Log-BUN (mmol/L) 1.39 (1.23-1.58) <0.0001 
  
  1.16 (1.02-1.32) 0.0233 
Log-NT-proBNP (ng/L) 1.30 (1.18-1.42) <0.0001 1.12 (1.02-1.23) 0.0205 1.14 (1.05-1.23) 0.0009 
Hemoglobin (g/dL) 0.79 (0.68-0.92) 0.0034 
  
  0.91 (0.88-0.95) <0.0001 
Hematocrit (g/dL) 1.05 (1.00-1.11) 0.0626 
  
  
   
Sodium (mmol/L) 0.97 (0.95-0.99) 0.0099 
  
  0.98 (0.96-1.00) 0.0026 
Log-Total Bilirubin 
(µmol/L) 
1.08 (0.92-1,28) 0.3589 
  
  1.11 (0.99-1.24) 0.0798 
Log-Alkaline Phosphatase 
(µg/L) 
1.38 (1.14-1.67) 0.0011 
  
  1.28 (1.09-1.51) 0.0035 
 HDL (mmol/L) 0.68 (0.51-0.90) 0.0075 0.69 (0.54-0.88) 0.0031 0.72 (0.57-0.90) 0.0042 
Use of beta-blocking 
agent at baseline 
0.75 (0.63-0.89) 0.0009 0.74 (0.62-0.88) 0.0007 0.76 (0.67-0.88) 0.0064 
 
Abbreviations: BUN: blood urea nitrogen; COPD: Chronic Obstructive Pulmonary Disease; DBP: Diastolic 
Blood Pressure; CI: Confidence Interval; DM: Diabetes Mellitus; eGFR: estimated Glomerular Filtration 
Rate; HDL: high density lipoprotein; HF: heart failure; HR: hazard ratio; NT-proBNP: N terminal pro Brain 
Natriuretic Peptide; SBP: Systolic Blood Pressure  
 Table 2: Results of the Cox Proportional Hazards analysis for the compact models 
predicting mortality, HF-hospitalization and the combined endpoint. 
                                     Mortality HF-Hospitalization     Combined endpoint 
  HR 95% CI p HR 95% CI p HR 95% CI p 
Age (years) 1.02 (1.01-1.03) <0.0001 1.01 (1.00-1.02) 0.0039 1.03 (1.02-1.04) <0.0001 
Heart failure 
hospitalization in last 
year 
  
  1.73 (1.47-2.04) <0.0001 1.52 (1.33-1.74) <0.0001 
Peripheral edema 
  
  1.54 (1.31-1.81) <0.0001 1.40 (1.23-1.61) <0.0001 
SBP (mmHg) 
  
  0.99 (0.99-0.99) <0.0001 0.99 (0.99-0.99) <0.0001 
eGFR (CKD-EPI 
formula)(ml/min)   
  0.99 (0.99-0.99) <0.0001 
   
Log-BUN (mmol/L) 1.52 (1.35-1.72) <0.0001   
 
  
   
Log-NT-proBNP 
(ng/L) 
1.40 (1.29-1.53) <0.0001   
 
  1.23 (1.15-1.33) <0.0001 
Hemoglobin (g/dL) 0.89 (0.85-0.93) <0.0001   
 
  0.90 (0.87-0.94) <0.0001 
HDL (mmol/L) 
   
  
 
  0.61 (0.48-0.78) <0.0001 
Sodium (mmol/L) 
   
  
 
  0.97 (0.96-0.99) 0.0002 
Use of beta-blocking 
agent at baseline 
0.76 (0.64-0.90) 0.0019       0.75 (0.65-0.86) <0.0001 
Abbreviations: BUN: blood urea nitrogen; CI: Confidence Interval; eGFR: estimated Glomerular Filtration 
Rate; HDL: high density lipoprotein; HF: Heart Failure; HR: Hazard Ratio; NT-proBNP: N terminal pro Brain 
Natriuretic Peptide  
 
  
 Table 3: C-statistic values of full and compact models for mortality, hospitalization and 
the combined endpoint. 
  Model  
development 
Model validation 
  Index cohort Internal (optimism 
corrected) 
External 
  Full Compact Full Compact Full Compact 
Mortality 0.73 0.69 0.73 0.69 0.73 0.73 
HF- Hospitalization 0.69 0.67 0.68 0.66 0.63 0.63 
Combined endpoint 0.71 0.69 0.70 0.69 0.68 0.68 
 
 
Table 4: C-statistic values of all models for mortality, hospitalization and the combined 
endpoint in HFrEF and HFpEF patients 
 Index cohort Validation cohort 
 Full compact Full compact 
 HFrEF HFpEF HFrEF HFpEF HFrEF HFpEF HFrEF HFpEF 
Mortality 0.73 0.65 0.69 0.64 0.74 0.72 0.72 0.71 
HF- Hospitalization 0.69 0.61 0.67 0.62 0.63 0.64 0.62 0.61 
Combined endpoint 0.71 0.62 0.70 0.61 0.68 0.69 0.67 0.67 
  
 Figure 1: Kaplan Meier survival curves for the point scale models (A: Mortality, B:HF-hospitalization, c: 
Combined endpoint) 
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 Supplementary data  
 
Table S1: Description of each variable used in model development (% (number), mean 
(sd) or median (interquartile range), with the % and number of values missing for 
patients 
  Index missing Validation missing 
Sex (% Male(n)) 73.4 (1846) 0% (0) 65.9 (1145) 0% (0) 
Age (years) 68.9 (±12) 0% (0) 73.7 (±10.7) 0% (0) 
Smoking   0% (0)   1% (12) 
          Past 48 (1220)  35 (602)  
          Current 14 (353)  13.7 (236)  
Alcohol usage 28 (700) 1% (4) 47 (790) 2% (40) 
Body mass index (kg/m2) 27.9 (±5.5) 2% (38) 28.1 (±6.4) 2% (35) 
Heart rate (bmp) 80 (±19.5) 1% (6) 74.2 (±16.6) 2% (38) 
Systolic blood pressure (mmHg) 124.7 (±21.9) 1% (5) 125.9 (±22.6) 2% (28) 
Diastolic blood pressure (mmHg) 74.9 (±13.4) 1% (5) 69.2 (±13.2) 2% (28) 
Left ventricular ejection fraction (%) 31 (±10.6) 11% (273) 41 (±13.0) 9% (163) 
HFpEF (LVEF>45%) (%)  7 (162)  11% (273) 34 (529)  9% (163) 
NYHA class   3% (70)   1% (1) 
          I 2.2 (56)  1.0 (17)  
          II 34.5 (868)  41.0 (712)  
          III 48.8 (1228)  44.4 (772)  
          IV 11.7 (294)  13.6 (236)  
Ischemic heart disease (%(n)) 60.5 (1358) 11% (273) 64.9 (1128) 0% (0) 
Hospitalization in past year before baseline (%(n)) 31.6 (794) 0% (0) 26.5 (460) 0% (0) 
History of atrial fibrillation (%(n)) 45.4 (1143) 0% (0) 43.7 (760) 1% (14) 
Diabetes mellitus 32.6 (819) 0% (0) 32.3 (561) 1% (9) 
Hypertension (%(n)) 62.4 (1569) 0% (0) 57.9 (1007) 1% (7) 
 eGFR (CKD-EPI formula)(ml/min) 64.4 (47.5-83.4) 6% (155) 66.1 (47.5-83.4) 1% (6) 
Myocardial infarction (%(n)) 38.3 (963) 0% (0) 48.8 (849) 1% (4) 
Coronary Artery Bypass Graft (%(n)) 17.2 (433) 0% (0) 17.7 (308) 1% (2) 
Percutaneous coronary intervention (%(n)) 21.6 (544) 0% (0) 18.7 (325) 1% (18) 
Stroke (%(n)) 9.3 (233) 0% (0) 18.1 (315) 1% (16) 
Peripheral artery disease (%(n)) 10.9 (273) 0% (0) 21.5 (374) 3% (45) 
Chronic Obstructive Pulmonary Disease (%(n)) 17.3 (436) 0% (0) 18.4 (319) 1% (15) 
Pulmonary congestion   3% (71)   5% (84) 
          Single base 12.7 (311)  5.7 (95)  
          Bi-basilar 40.1 (980)  38.7 (639)  
Edema (%(n)) 29.7 (624) 17% (417) 54.9 (955) 11% (192) 
Elevated Jugular venous pressure (%(n)) 22 (554) 34% (861) 25.9 (450) 0% (0) 
Hepatomegaly (%(n)) 14.3 (358) 1% (7) 3.5 (60) 10% (171) 
Rales >1/3 up lung fields (%(n)) 19.2 (248) 49% (1225) 2.9 (50) 0% (0) 
Baseline medication       
          Agents acting on the renin-angiotensin system (%(n)) 72.3 (1820) 0% (0) 70.1 (1218) 0% (0) 
          Beta-blocking agents (%(n)) 83.2 (2093) 0% (0) 72.7 (1264) 0% (0) 
Hematocrit (%) 40.1 (36.3-43.7) 11% (274) 40.5 (37.0-44.3) 1% (18) 
BUN (mmol/l) 11.1 (7.4-17.6) 12% (301) 8.6 (6.5-11.9) 1% (9) 
NT-proBNP (pg/ml) 4275 (2360-8485.5) 53% (1334) 1376 (510-3548) 2% (29) 
Sodium (mmol/l) 140 (137-142) 8% (189) 139.0 (137.0-141.0) 1% (7) 
Potassium (mmol/l) 4.2 (3.9-4.6) 8% (192) 4.3 (4.0-4.6) 1% (13) 
Bilirubin (µmol/l) 14 (10-21) 45% (1135) 10 (7-15) 1% (20) 
HDL cholesterol (mmol/l) 1 (0.8-1.3) 54% (1350) 1 (0.9-1.4) 4% (72) 
Alkaline Phosphatase (µg/L) 84 (65-117) 6% (156) 89 (72-116) 1% (10) 
Hemoglobin (g/dL) 13.3 (11.9-14.5) 9% (223) 13.2 (11.8-14.5) 1% (16) 
Albumine (g/L) 33 (27-38) 6% (156) 38 (34-42) 1% (13) 
Alanine aminotransferase (U/L) 25 (19-35) 39% (981) 22 (17-33) 1% (23) 
Aspartate aminotransferase (U/L) 25 (17-38) 28% (712) 23 (18-31) 6% (105) 
Glucose (mmol/L) 6.3 (5.5-7.9) 25% (622) 6.3 (5.2-8.4) 14% (248) 
 Abbreviations: BUN: blood urea nitrogen; eGFR: estimate Glomerular  
 Filtration Rate; HDL: High Density Lipoprotein; HFpEF: Heart failure with 
preserved ejection fraction, NYHA: New York Heart Association class; NT-
proBNP: N terminal pro Brain Natriuretic Peptide 
  
 Figure S1: Percentage of bootstrap samples each variables selected. Red and green line 
are the 40% full and compact model bootstrap sample variable selection lines. 
  
 Figure S2: Calibration plot of the compact model in the Index cohort. Gray is the optimal 
calibrationl, black are the uncorrected calibration lines and blue are the optimism 
corrected calibration lines  
  
 Figure S3: Calibration plot of the compact model in the validation cohort. 
 
  
 Table S2: Univariate analysis 
 Mortality  HF-Hospitalization                 Combined endpoint 
  HR 95% CI p HR 95% CI P HR 95% CI p 
Age (years) 1.03 (1.02-1.04) <0.0001 1.01 (1.00-1.02) 0.0005 1.02 (1.01-1.03) <0.0001 
Ischemic etiology 1.36 (1.16-1.61) 0.0002 
  
  
   
Heart failure 
hospitalization in last 
year  
  
  1.68 (1.43-1.98) <0.0001 1.46 (1.28-1.67) <0.0001 
Smoking 
  
  
  
  
   
          No 
  
  
  
  
 
- - 
          Past 
  
  
  
  1.12 (0.97-1.28) 0.1267 
          Current 
  
  
  
  1.42 (1.15-1.75) 0.0012 
DM 
  
  1.32 (1.12-1.57) 0.0009 
   
COPD 1.28 (1.07-1.54) 0.0084 1.00 
 
  1.17 (1.01-1.37) 0.0374 
NYHA class 
  
  
  
  
   
          NYHA class I 
  
  
  
  
 
- - 
          NYHA class II 
  
  
  
  1.17 (0.66-2.08) 0.5822 
          NYHA class III 
  
  
  
  1.46 (0.83-2.57) 0.1813 
          NYHA class IV 
  
  
  
  1.42 (0.79-2.56) 0.2441 
Peripheral edema 1.32 (1.11-1.58) 0.0021 1.28 (1.07-1.53) 0.0052 1.25 (1.08-1.44) 0.002 
Elevated Jugular venous 
pressure   
  
  
  
   
          No 
 
- - 
 
- - 
 
- - 
          Yes 1.25 (1.00-1.55) 0.0482 1.34 (1.10-1.62) 0.0029 1.22 (1.05-1.42) 0.0084 
Uncertain 1.14 (0.80-1.62) 0.4498 1.31 (0.89-1.93) 0.1725 1.16 (0.83-1.63) 0.3984 
DBP (mmHg) 0.99 (0.98-1.00) 0.0037 
  
  
   
SBP (mmHg) 1.00 (0.99-1.01) 0.2962 0.99 (0.99-0.99) <0.0001 0.99 (0.99-0.99) 0.0003 
eGFR (CKD-EPI 
formula)(ml/min)   
  0.99 (0.99-0.99) <0.0001 0.99 (0.99-0.99) 0.0064 
Log-BUN (mmol/L) 1.39 (1.23-1.58) <0.0001 
  
  1.16 (1.02-1.32) 0.0233 
Log-NT-proBNP (ng/L) 1.30 (1.18-1.42) <0.0001 1.12 (1.02-1.23) 0.0205 1.14 (1.05-1.23) 0.0009 
Hemoglobin (g/dL) 0.79 (0.68-0.92) 0.0034 
  
  0.91 (0.88-0.95) <0.0001 
Hematocrit (g/dL) 1.05 (1.00-1.11) 0.0626 
  
  
   
Sodium (mmol/L) 0.97 (0.95-0.99) 0.0099 
  
  0.98 (0.96-1.00) 0.0026 
Log-Total Bilirubin 
(µmol/L) 
1.08 (0.92-1,28) 0.3589 
  
  1.11 (0.99-1.24) 0.0798 
Log-Alkaline Phosphatase 
(µg/L) 
1.38 (1.14-1.67) 0.0011 
  
  1.28 (1.09-1.51) 0.0035 
HDL (mmol/L) 0.68 (0.51-0.90) 0.0075 0.69 (0.54-0.88) 0.0031 0.72 (0.57-0.90) 0.0042 
 Use of beta-blocking 
agent at baseline 
0.75 (0.63-0.89) 0.0009 0.74 (0.62-0.88) 0.0007 0.76 (0.67-0.88) 0.0064 
Abbreviations: CI: Confidence Interval; eGFR: estimate Glomerular Filtration Rate; HDL: High Density 
Lipoprotein; NYHA: New York Heart Association class; NT-proBNP: N terminal pro Brain Natriuretic 
Peptide 
